SAN DIEGO, Oct. 18 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical company, announced today that it will present an overview of the Company at the C.E. Unterberg, Towbin Specialty Pharmaceutical Conference in New York City. Prometheus will be one of only four privately-held companies to present at the conference. Prometheus' President and Chief Executive Officer, Joseph M. Limber, will make the presentation, which is scheduled for 11:20 a.m. Eastern Time, Wednesday, October 27, 2004.
Prometheus Laboratories Inc. is a specialty pharmaceutical company committed to developing new ways to help physicians individualize patient care. The Company focuses on the treatment, diagnosis and detection of gastrointestinal, autoimmune and inflammatory diseases and disorders. The Company's strategy includes the marketing and delivery of pharmaceutical products complemented by its proprietary, high-value diagnostic testing services. By integrating these therapeutic, diagnostic and treatment monitoring services, Prometheus addresses the continuum of patient care, thereby providing physicians with a comprehensive solution to treat chronic diseases. Prometheus' corporate offices are located in San Diego, California. Additional information about Prometheus Laboratories can be found at http://www.prometheuslabs.com/.
This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent that any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors. Prometheus cautions that any forward-looking information is not a guarantee of future performance. The Company may not achieve or maintain market acceptance of its products, or acquire, license or develop any other products for a variety of reasons. It is difficult to predict the impact of competitive products and pricing and new product development and launch. There can be no assurance that the Company can successfully commercialize or penetrate the market for its products.
Prometheus Laboratories Inc.
CONTACT: Beth Kriegel, Sr. Director, Financial Planning and InvestorRelations of Prometheus Laboratories Inc., +1-858-410-2516